Affimed price target raised to $10 from $5 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Affimed to $10 from $5 and keeps a Buy rating on the shares. The analyst says AFM24 could be an attractive target for a partnership. Positive data could position AFM24 as a viable therapy for the treatment of epidermal growth factor receptor non-small-cell lung cancer patients, the analyst tells investors in a research note.